Targeting the untargetable by merging biological and chemical compound libr...
Targeting the untargetable by merging biological and chemical compound libraries
"Genome sequencing combined with powerful new research technologies has greatly expanded the number of potential drug targets, offering enormous opportunities to address unmet medical needs. However, for proteins with flat, featur...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SAF2010-22198-C02-02
METODOS COMPUTACIONALES EN EL DISEÑO DE FARMACOS. NUEVAS APR...
242K€
Cerrado
CPTarget
Cyclic Peptide Platform as an Approach to Target Validation
2M€
Cerrado
BES-2011-046700
DESARROLLO DE COMPUESTOS PARA LA VALIDACION E IDENTIFICACION...
43K€
Cerrado
DNAeCLib
Drug Discovery using DNA encoded Chemistry
186K€
Cerrado
SAF2015-64629-C2-1-R
CARACTERIZACION Y BLOQUEO MEDIANTE PEPTIDOS Y MOLECULAS PEQU...
303K€
Cerrado
TNSBSLD
Targeting nucleic acid structures by site directed ligand di...
172K€
Cerrado
Información proyecto TARGET
Duración del proyecto: 67 meses
Fecha Inicio: 2021-05-22
Fecha Fin: 2026-12-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
"Genome sequencing combined with powerful new research technologies has greatly expanded the number of potential drug targets, offering enormous opportunities to address unmet medical needs. However, for proteins with flat, featureless surfaces or for protein-protein interactions, it has been difficult to impossible to generate ligands based on classical small molecules, hindering their evaluation as targets and the development of drugs.
Herein, we propose a new method and its application for targeting the so-called ""undruggable"" proteins by tapping into a new chemical space, generated by ""merging"" biological and chemical compound libraries. In brief, millions of short cyclic peptides (4–6 amino acids) genetically encoded by phage display (generated with methods we established previously) will be expanded by combinatorially attaching via lateral groups > 1000 different chemical fragments in separate wells of microwell plates. We will develop a strategy that combines the elements of i) automation, ii) liquid transfer by acoustic dispensing, iii) single-round phage display panning, iv) ""phage PCR"" and a primer coding strategy, v) next-generation sequencing (NGS) and vi) computational sequence analysis to perform phage display selections with a library comprising > 1000 non-natural building blocks.
We expect that this technology will deliver ligands to challenging proteins and facilitate their evaluation as drug targets. The ligands are kept small on purpose, below one kDa, and the polarity is limited so that they are more likely to be cell permeable and so they may directly serve as leads for the generation of oral drugs.
"